By Akanksha
Cord blood banking involves harvesting cord blood, which is stored after processing and freezing. Parents can store the cord blood for possible future uses. Once the umbilical cord is severed and discarded, the valuable stem cells within it can no longer be used. Although no family medical history may be known, there is no guarantee your child won't develop a medical condition that requires specialist treatment. As a result, many parents choose to bank their baby’s cord blood before birth to store a precious medical resource that may save lives if a family member experiences a medical emergency.
Cord blood banking has become widely recognized in recent years due to the huge potential for treating over 80 to 90 life-threatening medical conditions using stem cells. The field of umbilical cord blood banking and transplantation has expanded exponentially within the last 25 years. Over 600,000 cord blood units have been stored worldwide, with 30,000+ cord blood transplants completed.1
Umbilical cord blood provides an alternative source of hematopoietic stem cells for patients with hematological diseases that can be cured through allogeneic cell transplant.1 Only 30% of patients who require an allograft will have an HLA-matched sibling. Related and unrelated cord blood transplants have been performed with high success rates for a variety of hematological diseases and metabolic storage disorders in pediatric populations.1 It is important that a perfect HLA-match is made for bone-marrow transplants, but this is not as strict for cord blood transplants. There is a good chance that a cord blood sample with a few mismatched antigens will work well. Umbilical cord blood also carries a lower chance of developing Graft-Versus-Host Disease (GVHD).
There is a high success rate for curing beta-thalassemia or sickle-cell disease (SCD), through allogeneic transplantation from an HLA-compatible sibling.2 A study was conducted analyzing 44 children who received an allogeneic related cord blood transplant for beta-thalassemia (n=33) and sickle cell disease (n=11). None of the children died, and 36 children were cured, with a 79% likelihood of event-free survival at 2 years for thalassemia and a 90% likelihood of event-free survival at 2 years for sickle cell disease.2 Cord tissue, placental stem cells, and mesenchymal stem cells derived from cord tissue can also be stored.
Also Read: MAHA’s Treatments for Autism: Camel’s Milk, Stem Cell Injections — And Spelling Therapy
Both cord blood and cord tissue are collected from the umbilical cord at birth. Cord blood, the liquid stored within the umbilical vessels and placenta, contains high levels of hematopoietic stem cells (HSCs). These are widely used in clinical practice to treat over 80 diseases by regenerating a patient's blood and immune system. Cord tissue comes from the umbilical cord itself, specifically the protective, gel-like substance known as Wharton's jelly. It is rich in mesenchymal stem cells (MSCs), which develop into structural and connective tissues such as bone, cartilage, muscle, and nerve fibers. Consequently, while cord blood is already a standard treatment for blood-related conditions, cord tissue represents an investment in the rapidly expanding field of regenerative medicine. Clinical trials using cord tissue are currently underway to repair damaged organs, heal orthopedic injuries, and reduce inflammation in autoimmune diseases.
Private banking allows cord blood to be stored exclusively for the family. Parents pay to have the cord blood harvested, processed, and stored. Cord blood harvested from the baby will be a perfect match for them (100%) for autologous transplants. However, if an inherited genetic disorder develops in the child, then the cells stored will have the same genetic abnormality.
Siblings are important recipients for allogeneic transplants. Siblings will have inherited HLA markers from both parents, meaning there is 75% chance of a perfect or partial match between siblings. This includes a 25% chance of a perfect match and a 50% chance of a partial match. A child and either of their biological parents will share around 50 of their HLA markers, meaning they will be a partial match.
Public and private banking differ greatly in cost. Public banking allows parents to donate cord blood for any matching recipient, and donors usually do not pay anything. Public banks will often not charge families for storing cord blood, though this depends on the hospitals involved and whether the donor is eligible.
The most important thing to consider when looking at stem cell storage is that the lab standards allow the cells to be stored in cryogenic conditions for many years. Parents should disregard any marketing material and make sure the provider has current licenses and accreditations.
DCGI (Drugs Controller General of India): This is the national regulatory body that issues the legal license to all cord blood banks within India. The DCGI license is a mandatory requirement and must come with State FDA approval. This license ensures that the stem cell lab is operating to a high standard. They will have clean rooms, the mother will be tested for infectious diseases (HIV, hepatitis B and C, and syphilis), and bacterial and fungal cultures will be performed. The stem cells will then be accurately counted.
AABB (Association for the Advancement of Blood & Biotherapies): This was previously known as the American Association of Blood Banks and is an international non-profit organization that sets global standards for blood and cellular therapy labs. This accreditation will ensure you have a high-standard lab. They will regularly audit the lab every two years to ensure your collection kits are sterile, samples are stored at the correct temperature, and units are properly reduced and stored in liquid nitrogen.
FACT (Foundation for the Accreditation of Cellular Therapy): This was co-founded by the International Society for Cell & Gene Therapy (ISCT) and the American Society for Transplantation and Cellular Therapy (ASTCT). NetCord-FACT is widely recognized as the highest standard in the world by transplant hematologists. This accreditation ensures that all processes throughout the lifecycle of the stem cell unit are completed to a high standard. They ensure not just that the cells are properly frozen, but also that when needed for a transplant, they are properly thawed, tested for viability after thawing, and matched to the patient.
CAP, NABL & WHO-GMP: Parents should also look for labs that have a CAP (College of American Pathologists) or NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation. This will ensure the labs are accurately testing and analyzing the blood samples. They should also have a WHO-GMP (Good Manufacturing Practices) certificate, which ensures the lab is operating to a pharmaceutical standard. Many transplant centers around the world will not accept stem cell units from labs without these accreditations.
Cord blood collection may be charged separately depending on the hospital where your baby is delivered. Cord blood is harvested post-delivery once the cord has been served, so there is no pain for the baby or mother. All private cord blood banking includes laboratory testing, processing, and quality checks. The official guidelines provided by the Indian Council of Medical Research provide information on how to safely and ethically collect, process, test, store, bank, and release umbilical cord blood. For example, 19 parameters are tested on the harvested stem cells at LifeCell. Cord tissue and other biological samples can also be stored in bundled packages.
Founded in 2004 with dual state-of-the-art facilities in Chennai and Gurugram, LifeCell is India's largest private provider. It revolutionized the domestic market by pioneering a Community Banking model alongside traditional private storage.
Rather than restricting storage strictly to the individual family, community banking allows enrolled members to access a shared registry of tens of thousands of verified, HLA-typed cord blood units, significantly expanding matching probabilities for transplants.
DCGI-licensed; holds international credentials including AABB, CAP (College of American Pathologists), NABL, WHO-GMP, and compliance with ISBT 128 uniform barcoding and USFDA establishment standards.
Established in 2006 and backed by the multinational conglomerate RJ Corp, Cryoviva operates a high-capacity, automated processing and cryogenic storage facility in Gurugram, with an extensive operational network spanning multiple countries across Asia and Africa.
Provides traditional private family banking as well as expanded multi-tier options, combining automated liquid nitrogen cryo-storage monitoring with comprehensive transport logistics and financial assistance provisions for transplants.
Fully licensed by the DCGI and accredited by AABB, CAP, and cGMP/ISO cleanroom standards.
Operating out of the advanced life sciences cluster at the Apollo Hospitals campus in Gandhinagar, StemCyte India is a specialized joint venture involving international biotechnology expertise and major clinical infrastructure.
Focuses on both private family banking and public/hybrid registries, maintaining a strong emphasis on clinical-grade processing standards designed to support active cellular therapies and global transplant networks.
Stands out as one of the few facilities in India holding NetCord-FACT accreditation, the highest clinical standard in cellular therapy, alongside DCGI licensing, AABB accreditation, NABL, and cGMP compliance.
Headquartered in Kolkata with advanced laboratory infrastructure near the city's tech and medical corridors, Cordlife India is an established subsidiary of the Singapore-headquartered Cordlife Group.
Offers private family banking with specialized technological platforms, including automated separation systems (such as AXP® II) for maximal stem cell recovery and proprietary cord-lining methods (EpiCord and Explant) to isolate both mesenchymal and epithelial stem cells from cord tissue.
Licensed by the DCGI and internationally accredited by AABB, CAP, NABL, WHO-GMP, and ISO 9001.
Based in Mumbai, ReeLabs operates a specialized stem cell processing and regenerative medicine facility focused on multi-source biological asset preservation.
Differentiates itself by offering comprehensive multi-source tissue banking, preserving umbilical cord blood and cord tissue alongside alternative cellular sources such as placenta, amniotic sac, and adipose tissue.
Holds DCGI licensing, WHO-GMP, GLP, and ISO 9001:2015 certifications, operating under internal institutional ethics oversight for clinical protocols.
Located within the historic academic and hospital campus in Kolkata, the Cord Blood Bank at STM is India’s first government-run public cord blood bank, established under the Department of Health & Family Welfare, Government of West Bengal.
Operates entirely on a public donation model. Expectant mothers delivering at designated government medical facilities can voluntarily donate their baby's umbilical cord blood completely free of cost (₹0). Collected units are processed, screened, and pooled into a public inventory to treat underprivileged patients suffering from blood disorders and malignancies.
Operates under strict state medical governance and national regulatory frameworks as an authorized public repository.
Headquartered in Chennai, Jeevan is a prominent non-profit public trust that operates India's largest public cord blood registry, having worked closely with state and central health authorities.
Functions on a philanthropic public banking framework where cord blood collection is entirely voluntary and free of charge (₹0). Donations are cataloged in an open registry, making matching stem cell units accessible to any patient across India or internationally requiring a life-saving transplant.
Complies with national ethical guidelines for public stem cell banking and repository management under medical oversight.
Private cord blood banking in India generally costs between ₹49,000 and ₹80,000 for standard long-term prepaid packages. The total investment depends primarily on the chosen storage duration and whether families select cord-blood-only storage or combined cord blood and tissue packages.
LifeCell: Offers an annual renewal plan starting at ₹20,330 (plus testing and processing fees). Prepaid multi-decade options include the 21-year plan at ₹49,144 and the 75-year lifetime plan at ₹63,551. Expanded community or bundled tier packages range from ₹98,000 to ₹1,34,000.
StemCyte: Features hybrid and private plans starting with the StemCyte Pro 21-year plan at ₹55,000, the StemCyte Prime 75-year plan at ₹70,000, and the StemCyte Elite 75-year plan at ₹80,000.
Cryoviva: The Super-Saver 21-year plan starts around ₹55,400, while comprehensive multi-tier and bundled family packages range from ₹66,500 upwards depending on tissue and advanced cell-processing inclusions.
Headline package rates rarely represent the final out-of-pocket figure. Providers like LifeCell and StemCyte explicitly note that 18% GST and sample collection fees (charged by the delivering hospital or medical staff, typically ranging from ₹3,000 to ₹5,000) are billed extra. To make upfront payments manageable, leading banks offer flexible financing structures, such as LifeCell's interest-free EMI plans starting at ₹3,383 per month with nominal down payments.
Also Read: Stem Cell Therapy Reverses Type 2 Diabetes in China
When researching cord blood banking costs in India, ensure you look at the overall package and what is included. Ensure the bank has the correct accreditations, such as DCGI, AABB, FACT. The overall cost will depend on GST, sample collection, retrieval, and what is included in the package, so always request a written breakdown of costs before deciding.
References:
1. Ballen, Karen K., Eliane Gluckman, and Hal E. Broxmeyer. “Umbilical Cord Blood Transplantation: The First 25 Years and Beyond.” Blood 122, no. 4 (July 25, 2013): 491–98.
https://pubmed.ncbi.nlm.nih.gov/23673863/.
2. Locatelli, Franco, Vanderson Rocha, William Reed, et al. “Related Umbilical Cord Blood Transplantation in Patients with Thalassemia and Sickle Cell Disease.” Blood 101, no. 6 (March 15, 2003): 2137–43.
https://pubmed.ncbi.nlm.nih.gov/12424197/.
3. Indian Council of Medical Research. Guidelines for Umbilical Cord Blood Banking: Collection, Processing, Testing, Storage, Banking and Release for Clinical Application. Ministry of Health and Family Welfare, Government of India, 2023.
https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/GUCBB_F.pdf.
4. Matsumoto, T., and H. Mugishima. “Non-Hematopoietic Stem Cells in Umbilical Cord Blood.” International Journal of Stem Cells 2, no. 2 (2009): 83–89.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4021761/.
(OG/APC/MSM)
